In addition, they confirmed published findings on the impact of NB73 on triple negative breast cancer (TNBC) [9] indicating that NB73 is superior to previously developed FOXM1 inhibitors such as FDI-6 [18] and the peptide thiazole antibiotics, thiostrepton [19] and siomycin A [20]. The gene discussed is FOXM1; the disease is triple-negative breast carcinoma.